What dosing schedule does ipilimumab use for cancer treatment?
Ipilimumab dosing depends on the indication. The two most common schedules used clinically are:
- 3 mg/kg given intravenously (IV) every 3 weeks for 4 doses, for a total of 12 weeks in the common regimen.
- 1 mg/kg given IV every 6 weeks for 4 doses, in regimens where ipilimumab is used at a lower dose.
How is ipilimumab given (dose, route, and timing)?
Ipilimumab is administered as an IV infusion. The schedule is set by the treatment plan for the specific disease and regimen (including whether ipilimumab is combined with other immunotherapies). The frequency is typically every 3 weeks (for the higher-dose schedule) or every 6 weeks (for the lower-dose schedule), with a fixed number of doses.
What happens if a dose is missed or treatment is delayed?
If an infusion is missed or delayed, clinicians typically adjust the timing based on the reason for delay and the patient’s clinical status. Dosing is usually resumed when appropriate, while also considering immune-related side effects (if they occurred). The exact approach depends on the patient’s indication, prior cycle timing, and tolerability.
Does ipilimumab dosing differ when combined with nivolumab?
Yes. Many combination regimens use different dosing than single-agent ipilimumab. In practice, the schedule follows the studied protocol for the specific combination regimen (for example, higher-dose ipilimumab in a more frequent schedule versus lower-dose ipilimumab in less frequent dosing).
How long does a full ipilimumab course last?
For the commonly used fixed-dose cycles:
- Every 3 weeks for 4 doses spans about 12 weeks of dosing time.
- Every 6 weeks for 4 doses spans about 18 weeks of dosing time.
What side effects affect whether dosing continues?
Ipilimumab is associated with immune-mediated adverse events (immune-related toxicities). If side effects occur—especially moderate to severe immune-mediated inflammation—clinicians may hold the next dose, reduce intensity per protocol, or stop treatment depending on severity and organ involvement.
What dosing details should a patient verify with their clinician?
Patients should confirm the exact:
- Dose in mg/kg and infusion frequency (every 3 weeks vs every 6 weeks)
- Number of doses planned
- Whether ipilimumab is single-agent or combined with another drug
- The monitoring plan for immune-related side effects, which can change dosing decisions
Sources
I don’t have enough provided information in your prompt to cite dosing specifics from a particular label or guideline. If you share the cancer type/indication (or whether it’s ipilimumab alone vs combined), I can give the exact dosing schedule for that regimen.